Risk Factors, Pattern and Clinical Outcome of Acute Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplant

Overview

Journal Indian J Hematol Blood Transfus

Specialty Hematology

Date 2015 Aug 26

PMID 26306063

Citations 3

Authors

Alok Gupta

Sachin Punatar

Jayant Gawande

Libin Mathew

Bhausaheb Bagal

Sadhana Kannan

Navin Khattry

Affiliations

Soon will be listed here.

Abstract

We sought to determine risk factors, pattern and outcome of acute graft versus host disease (aGVHD) in seventy-seven acute leukemia patients who underwent allogeneic stem cell transplant at our centre from January 2008 to March 2013. GVHD prophylaxis with cyclosporine-methotrexate or cyclosporine-mycophenolate mofetil was used. Patients were divided in 2 groups, grade II-IV aGVHD (group A) and grade 0-I aGVHD (group B). Incidence of any grade and grade II-IV aGVHD was 44 and 18 %, respectively. The most common site of aGVHD was gastro-intestinal tract (65 %) followed by skin (35 %). Higher total nucleated cell (TNC) dose infused was associated with increased incidence of grade II-IV aGVHD. Incidence of relapse and incidence of slippage of chimerism was 21 and 36 % in group A while 37 and 27 % in group B respectively. Transplant related mortality (TRM) was 21 % in group A and 13 % in group B. Probability of OS and RFS at 4 years was 63 and 34 % in group A compared with 40 and 38 % in group B, respectively. We conclude that higher TNC dose infused is a risk factor for grade II-IV aGVHD with gut being the commonest site. Grade II-IV aGVHD did not have a significant impact on incidence of relapse, TRM and OS.

Citing Articles

Clinical significance of total nucleated cell count in bone marrow of patients with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation.

Nukui J, Tachibana T, Miyazaki T, Tanaka M, Matsumoto K, Ishii Y Int J Hematol. 2023; 119(1):62-70.

PMID: 38082200 DOI: 10.1007/s12185-023-03688-7.

Understanding and treatment of cutaneous graft-versus-host-disease.

Hong J, Fraebel J, Yang Y, Tkacyk E, Kitko C, Kim T Bone Marrow Transplant. 2023; 58(12):1298-1313.

PMID: 37730800 PMC: 11759061. DOI: 10.1038/s41409-023-02109-x.

Comparison of Outcomes of Donor Lymphocyte Infusions With or Without Lenalidomide in Patients with Hematological Malignancies Post Allogeneic HSCT.

Punatar S, Murugaiyan V, Kumbhalwar K, Gokarn A, Chichra A, Mirgh S Indian J Hematol Blood Transfus. 2023; 39(1):40-49.

PMID: 36699432 PMC: 9868208. DOI: 10.1007/s12288-022-01545-x.

References

Hahn T, McCarthy Jr P, Zhang M, Wang D, Arora M, Frangoul H . Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol. 2008; 26(35):5728-34. PMC: 2645611. DOI: 10.1200/JCO.2008.17.6545. View

Goldman J, Gale R, Horowitz M, BIGGS J, Champlin R, Gluckman E . Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988; 108(6):806-14. DOI: 10.7326/0003-4819-108-6-806. View

Mielcarek M, Martin P, Leisenring W, Flowers M, Maloney D, Sandmaier B . Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003; 102(2):756-62. DOI: 10.1182/blood-2002-08-2628. View

Gale R, BORTIN M, van Bekkum D, BIGGS J, Dicke K, Gluckman E . Risk factors for acute graft-versus-host disease. Br J Haematol. 1987; 67(4):397-406. DOI: 10.1111/j.1365-2141.1987.tb06160.x. View

Shulman H, Sullivan K, Weiden P, McDonald G, Striker G, Sale G . Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980; 69(2):204-17. DOI: 10.1016/0002-9343(80)90380-0. View

Jagasia M, Arora M, Flowers M, Chao N, McCarthy P, Cutler C . Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2011; 119(1):296-307. PMC: 3251233. DOI: 10.1182/blood-2011-06-364265. View

Champlin R, Schmitz N, Horowitz M, Chapuis B, Chopra R, Cornelissen J . Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2000; 95(12):3702-9. View

Ali M, Oyama Y, Monreal J, Winter J, Tallman M, Gordon L . Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 x 10(9)/l neutrophils on 3 consecutive days to define myeloid recovery. Bone Marrow Transplant. 2002; 30(11):749-52. DOI: 10.1038/sj.bmt.1703741. View

Mohty M, Gaugler B . Inflammatory cytokines and dendritic cells in acute graft-versus-host disease after allogeneic stem cell transplantation. Cytokine Growth Factor Rev. 2007; 19(1):53-63. DOI: 10.1016/j.cytogfr.2007.10.010. View

10.

Garcia Cadenas I, Valcarcel D, Martino R, Pinana J, Barba P, Novelli S . Impact of cyclosporine levels on the development of acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation. Mediators Inflamm. 2014; 2014:620682. PMC: 3929065. DOI: 10.1155/2014/620682. View

11.

Barrett A, Ringden O, Zhang M, Bashey A, Cahn J, Cairo M . Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood. 2000; 95(11):3323-7. View

12.

Sorror M, Maris M, Storer B, Sandmaier B, Diaconescu R, Flowers C . Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004; 104(4):961-8. DOI: 10.1182/blood-2004-02-0545. View

13.

Malard F, Szydlo R, Brissot E, Chevallier P, Guillaume T, Delaunay J . Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2010; 16(1):28-34. DOI: 10.1016/j.bbmt.2009.08.010. View

14.

Couriel D, Saliba R, Giralt S, Khouri I, Andersson B, de Lima M . Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant. 2004; 10(3):178-85. DOI: 10.1016/j.bbmt.2003.10.006. View

15.

Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I . Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 2001; 98(6):1695-700. DOI: 10.1182/blood.v98.6.1695. View

16.

Gaziev J, Isgro A, Marziali M, Daniele N, Gallucci C, Sodani P . Higher CD3(+) and CD34(+) cell doses in the graft increase the incidence of acute GVHD in children receiving BMT for thalassemia. Bone Marrow Transplant. 2011; 47(1):107-14. DOI: 10.1038/bmt.2011.3. View

17.

Izumi N, Furukawa T, Sato N, Okazuka K, Tsukada N, Abe T . Risk factors for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: retrospective analysis of 73 patients who received cyclosporin A. Bone Marrow Transplant. 2007; 40(9):875-80. DOI: 10.1038/sj.bmt.1705834. View

18.

Glucksberg H, Storb R, Fefer A, Buckner C, Neiman P, Clift R . Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974; 18(4):295-304. DOI: 10.1097/00007890-197410000-00001. View

19.

Wakui M, Okamoto S, Ishida A, Kobayashi H, Watanabe R, Yajima T . Prospective evaluation for upper gastrointestinal tract acute graft-versus-host disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 1999; 23(6):573-8. DOI: 10.1038/sj.bmt.1701613. View

20.

Ratanatharathorn V, Nash R, Przepiorka D, Devine S, Klein J, Weisdorf D . Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998; 92(7):2303-14. View